Concepedia

Publication | Closed Access

Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09

DOI

74

Citations

0

References

1994

Year

Jan H.M. Schellens, André Planting, B.A.C. van Acker, Walter J. Loos, M de Boer-Dennert, M.E.L. van der Burg, I. Koier, Raymond T. Krediet, G. Stoter, Jaap Verweij
JNCI Journal of the National Cancer Institute

Abstract

The MTD of E09 was determined to be 27 mg/m2. The standard approach of drug administration is considered unsuitable because of potential renal toxicity and wide variability in the pharmacokinetics of E09. Individual dose adjustments based on plasma concentration measurements are recommended to combine maximally achievable exposure with tolerable toxicity.